| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514200800 | Gram negative bacterium (e.g., Escherichia coli, salmonella, Helicobacter, etc.) | 71 |
| 20100267645 | Methods and compositions for treating ocular disease - The use of collectins and/or surfactant proteins for the treatment and prevention of ocular disease. | 10-21-2010 |
| 20100267646 | Trophic Factor for the Treatment of Retinal Degenerative Diseases - This invention relates to methods and compositions for detection and treatment of retinal degenerative diseases. In particular, the invention relates to polypeptides that can protect against cone degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides. | 10-21-2010 |
| 20100267647 | MODULATING PHOTOREACTIVITY IN A CELL - Photoreactivity in a cell is modulated by incorporating an isolated optical trigger on the surface or in the membrane of the cell. Exposure of a cell bearing incorporated optical triggers causes the generation of a measurable physiological signal. | 10-21-2010 |
| 20100273720 | Protective Complement Proteins and Age-Related Macular Degeneration - Methods for identifying a subject at risk for developing AMD are disclosed. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material. Therapeutic compositions and methods are also provided for delaying the progression or onset of the development of AMD in a subject, including treating a subject having signs and/or symptoms of AMD or who has been diagnosed with AMD. | 10-28-2010 |
| 20100273721 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISORDERS - The present invention relates to compositions and methods for treating ophthalmic disorders of humans or animals. The present compositions and methods are highly suitable for intraocular administration into the interior of an eye and provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision. More specifically, the present invention relates to compositions and methods for treating ophthalmic diseases or disorders with exudative, hemorrhagic and/or inflammatory conditions. Even more specifically, the present invention relates to compositions and methods for treating retinal diseases or disorders, and more specifically ophthalmic diseases or disorders related to impaired retinal vessel permeability and/or integrity. | 10-28-2010 |
| 20110015136 | humanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration - Methods and compositions for treating a subject having age-related macular degeneration (AMD), methods of assaying human macular degeneration (MD), and methods and kits for assaying potential therapeutic agents for treatment of human MD are provided herein. | 01-20-2011 |
| 20110059902 | Therapeutic Replenishment and Enrichment of Ocular Surface Lubrication - The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration. | 03-10-2011 |
| 20110071091 | INJECTABLE AQUEOUS OPHTHALMIC COMPOSITION AND METHOD OF USE THEREFOR - The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in creating a desirable release profile of therapeutic agent. | 03-24-2011 |
| 20110086807 | FIBROMODULIN FORMULATION FOR REDUCING CORNEAL SCARRING - A formulation for reducing corneal scarring and related eye conditions, is disclosed. The formulation comprises an effective amount of fibromodulin and can be administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye. | 04-14-2011 |
| 20110105410 | Beta-Turn Peptidomimetic Cyclic Compounds for Treating Dry Eye - The present invention relates to methods of treating dry eye using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye. | 05-05-2011 |
| 20110105411 | Disease-Associated Proteins - Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions. | 05-05-2011 |
| 20110112038 | NOVEL NPR-B AGONISTS - Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds. | 05-12-2011 |
| 20110130345 | ALPHA CONNEXIN C-TERMINAL (ACT) PEPTIDES FOR TREATING AGE-RELATED MACULAR DEGENERATION - Provided herein are compositions and methods for use in treating or preventing macular degeneration in a subject. | 06-02-2011 |
| 20110144035 | Methods and Compositions for Treating Conditions of the Eye - Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature. | 06-16-2011 |
| 20110172164 | BI-DENTATE COMPOUNDS AS KINASE INHIBITORS - The present disclosure provides compound having the general structure A or pharmaceutically acceptable salts thereof: | 07-14-2011 |
| 20110212899 | Corneal Neuritogenesis Promoter Containing Pacap and Its Derivative - It is intended to provide an agent for promoting corneal neuritogenesis containing PACAP, a PACAP derivative or a pharmaceutically acceptable salt thereof, in particular, an agent for promoting corneal neuritogenesis aiming at improving corneal sensitivity, treating dry eye and treating corneal epithelial injury due to an effect of promoting corneal neuritogenesis. This agent for promoting corneal neuritogenesis is useful as a drug for ameliorating reduction in corneal sensitivity following corneal surgeries such as laser keratonomy (LASIK) and corneal grafting or cataract surgery, reduction in corneal sensitivity accompanying corneal neurodegeneration and dry eye symptom and corneal epithelial injury accompanying such reduction in corneal sensitivity. Moreover, it is useful as a drug for ameliorating dry eye symptom, reduction in corneal sensitivity and corneal epithelial injury in patients with dry eye, and a drug for ameliorating corneal epithelial injury and dry eye symptom and reduction in corneal sensitivity accompanying therewith. | 09-01-2011 |
| 20110230424 | OPHTHALMIC SOLUTIONS, INCLUDING CONTACT LENS CARE AND EYE DROPS COMPRISING CARNOSINE, PREFERABLY IN COMBINATION WITH DEXPANTHENOL AND/OR HYALURONIC ACID - The current invention relates to a contact lens care solution comprising a compound suitable for treating the eye, or the contact lens, use of such compound in such contact lens care solutions, and methods for introducing such compound in the eye of a person wearing contact lenses. With the current invention damage to the eye, in particular the cornea, in particular damage to the eye, in particular the cornea, of a person wearing a contact lens, or as a consequence of wearing a contact lens is prevented or reduced./esp. | 09-22-2011 |
| 20110251137 | GAMMA-POLYGLUTAMIC ACID-BASED OCULAR IRRIGATING SOLUTIONS - Ophthalmic irrigating solutions are disclosed. The ophthalmic irrigating solution comprises: a) γ-polyglutamic acid (γ-PGA) and/or salt thereof in an amount effective to increase the viscosity of the irrigating solution; and b) an ophthalmically acceptable aqueous vehicle for the γ-PGA and/or salt thereof. Also disclosed is a method of irrigating ocular tissues of a patient, in which the method comprises introducing to the ocular tissues of the patient an ophthalmic irrigating solution comprising γ-PGA) and/or salt thereof in an amount sufficient to irrigate the ocular tissues of the patient. | 10-13-2011 |
| 20110257103 | Compositions and methods for the treatment of sj?rgren's syndrome - This invention provides a method of inducing a lacrimal acinar cell in a tissue to degrade a secretory vesicle and its content protein or proteins from the trans-Golgi network (TGN) by contacting the cells with an effective amount of an agent that induces autophagy. Also provided is a method for treating a mammal suffering from defective trans-Golgi network-secretory vesicle (TGN-SV) sorting by administering to the mammal an effective amount of an agent that induces autophagy in the tissue having the defective TGN-SV. | 10-20-2011 |
| 20110294745 | SOLUTIONS OF LIPOPHILIC SUBSTANCES, ESPECIALLY MEDICINAL SOLUTIONS - The present invention relates to a solution containing at least one water-miscible biocompatible solvent and a lipophilic substance dissolved therein, wherein upon contact with aqueous body fluid the dissolved lipophilic substance is precipitated out of the solution in the form of nanoparticles and a nanosuspension is formed. | 12-01-2011 |
| 20120022002 | SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY - The present invention provides an ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein said complex is associated with a biocompatible polymer. Said biocompatible polymer comprises a polymeric matrix configured to release said complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease. | 01-26-2012 |
| 20120022003 | METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM - The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: | 01-26-2012 |
| 20120101046 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR RETINAL DISEASE AND METHOD FOR PROPHYLAXIS OR THERAPY OF RETINAL DISEASE USING JNK (C-JUN AMINO-TERMINAL KINASE) - INHIBITORY PEPTIDE, AND USE OF THE PEPTIDE - Intravitreal administration of a JNK-inhibitory peptide less than 150 amino acids in length, containing at least one D-amino acid, and having (a) a JNK-inhibitory sequence of at least any of SEQ ID NO: 1 and SEQ ID NO: 2, and (b) a transport sequence of at least any of SEQ ID NO: 3 and SEQ ID NO: 4 suppressed spermidine-induced retinal pigment epithelial damage, tunicamycin-induced photoreceptor cell damage, and laser-induced choroidal neovascularization. Thus, the JNK-inhibitory peptide of the present invention is useful for prophylaxis or therapy of a retinal disease. By the use of this JNK-inhibitory peptide, a drug and a method are provided which are capable of preventing or treating a retinal disease even by topical administration to the eye, and use of the JKN-inhibitory peptide for manufacturing the drug is also provided. | 04-26-2012 |
| 20120115794 | USE OF CD44V6 IN THE TREATMENT OF OPHTHALMIC DISEASES - The present invention relates to the use of peptide compounds for the prevention and/or treatment of ophthalmic diseases. In particular, the present invention relates to a peptide compound comprising an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 2 (KEQWFGNRWHEGYR) or of SEQ ID NO: 1 (KEKWFENEWQGKNP), or a functionally active derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatmend of an ophthalmic disease in an individual. While SEQ ID NO: 2 is a part of the human CD44v6, SEQ ID NO: 1 is a part of the rat CD44v6. | 05-10-2012 |
| 20120142608 | RCA LOCUS ANALYSIS TO ASSESS SUSCEPTIBILITY TO AMD AND MPGNII - The invention relates to gene polymorphisms and genetic profiles associated with an elevated or a reduced risk of alternative complement cascade deregulation disease such as AMD and/or MPGNII. The invention provides methods and reagents for determination of risk, diagnosis and treatment of such diseases. In an embodiment, the present invention provides methods and reagents for determining sequence variants in the genome of a individual which facilitate assessment of risk for developing such diseases. | 06-07-2012 |
| 20120142609 | NON HUMAN ANIMAL MODELS FOR INCREASED RETINAL VASCULAR PERMEABILITY - The present invention relates to a non human animal model for increased retinal vascular permeability wherein said increased retinal vascular permeability is induced by inhibiting in Müller cells of said animal the expression of a gene encoding for Dp71 or a dystrophin associated protein (DAP). Furthermore, the present invention relates to methods and compositions for the treatment of a disease associated with an increased retinal vascular permeability in a subject in need thereof. | 06-07-2012 |
| 20120165271 | METHODS OF TREATING RETINITIS PIGMENTOSA - The present invention relates to methods of treating retinitis pigmentosa using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs useful in treating retinitis pigmentosa. | 06-28-2012 |
| 20120165272 | Tear Substitutes - The invention features ophthalmic formulations of mucin polypeptides to treat or prevent dry eye. | 06-28-2012 |
| 20120165273 | EYE DROPS - An eyedrop containing a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg (“SSSR”), or a pharmacologically acceptable salt thereof; and a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH | 06-28-2012 |
| 20120190629 | LIGHT-RECEIVING CHANNEL RHODOPSIN HAVING IMPROVED EXPRESSION EFFICIENCY - Disclosed is a Volvox carteri-derived light-receiving channel rhodopsin with an improved expression efficiency on a cell membrane. Specifically disclosed is a modified Volvox carteri-derived light-receiving channel rhodopsin protein. The protein is modified to contain an N-terminal region of Chlamydomonas reinhardtii-derived channel rhodopsin-1 at the N-terminal of the Volvox carteri-derived light-receiving channel rhodopsin protein, wherein the N-terminal region is involved in cell membrane-localized expression and contains no transmembrane domain of the Chlamydomonas reinhardtii-derived channel rhodopsin-1. | 07-26-2012 |
| 20120232019 | Compositions and Methods for Treatment of Eye Disorders - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 09-13-2012 |
| 20120245102 | PARTIAL PEPTIDE OF LACRITIN - The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution. | 09-27-2012 |
| 20120322747 | BETA-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS FOR TREATING DRY EYE - The present invention relates to methods of treating dry eye using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye. | 12-20-2012 |
| 20130040896 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction. | 02-14-2013 |
| 20130045926 | COMPOSITION AND METHODS FOR THE PREVENTION AND TREATMENT OF MACULAR DEGENERATION, DIABETIC RETINOPATHY, AND DIABETIC MACULAR EDEMA - Methods of stabilizing and organizing collagen fibrils in extracellular matrix of retinal tissues, particularly Bruch's membranes, and stabilizing retinal pigment epithelial layers lining Bruch's membrane are disclosed. The stabilization and organization may be effected by treating retinal tissues with a protein that crosslinks and organizes collagen fibrils, such as decorin. The stabilization and organization methods include treatment of retinal tissues before, during, or after diagnosis of dry macular degeneration, diagnosis of early stages of diabetic retinopathy and diabetic macular edema to prevent, retard, or limit progression of disorganization of Bruch's membrane and disorganization of retinal pigment epithelial cells lining Bruch's membrane. | 02-21-2013 |
| 20130045927 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE - Described herein are materials and methods of treating dry eye disease in a subject. | 02-21-2013 |
| 20130072442 | Viral Complement Control Proteins for Eye Disorders - The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject. | 03-21-2013 |
| 20130072443 | STABILIZED MUTANT OPSIN PROTEINS - Methods and compositions for stabilizing opsin protein in a vertebrate visual system are provided by administration of opsin-binding synthetic retinoids. | 03-21-2013 |
| 20130102544 | Disease-Associated Proteins - Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions. | 04-25-2013 |
| 20130109632 | USE OF VEGFR-2 IN THE TREATMENT OF OPHTHALMIC DISEASES | 05-02-2013 |
| 20130116197 | MODIFIED BINDING PROTEINS INHIBITING THE VEGF-A RECEPTOR INTERACTION - The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration. | 05-09-2013 |
| 20130157963 | OPHTHALMIC COMPOSITIONS COMPRISING POLYVINYL CAPRALACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMERS - Compositions and methods related to ophthalmic use of polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein. | 06-20-2013 |
| 20130203680 | FOLATE CONJUGATES FOR TREATING INFLAMMATION OF THE EYE - The present invention relates to methods of use of folate conjugates for treating inflammatory diseases of the eye, to folate conjugates for use in treating inflammatory diseases of the eye, and to folate conjugates for use in the manufacture of a medicament for treating inflammatory diseases of the eye. More particularly, the invention is directed to the use of folate linked to one or more anti-inflammatory agents for each of the above-described uses. | 08-08-2013 |
| 20130225505 | MUTEINS OF HUMAN TEAR LIPCALIN FOR TREATING NEOVASCULAR DISEASE OF THE ANTERIOR SEGMENT OF THE HUMAN EYE - Disclosed herein is a method of treating neovascular diseases of the anterior segment of the human eye, the method comprising administering to the eye muteins of human tear lipocalin that target VEGF. | 08-29-2013 |
| 20130288985 | COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS - This application discloses pharmaceutical compositions (e.g., oral, parenteral or topical ophthalmic formulations) for treating Fuchs endothelial corneal dystrophy (FECD) with one or more Nrf2 activators and/or mitochondrially targeted antioxidants. The compositions may be topically administered to the eye and are effective in the treatment of FECD. The invention further provides methods of treating FECD by in a subject in need of such treatment by topical application of one or more Nrf2 activators and/or mitochondrially of the invention. | 10-31-2013 |
| 20130296254 | COMPSTATIN AND ANALOGS THEREOF FOR EYE DISORDERS - The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions. | 11-07-2013 |
| 20130296255 | Methods and Reagents for Treatment of Age-Related Macular Degeneration - The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD. | 11-07-2013 |
| 20130310326 | Histatin for Corneal Wound Healing and Ocular Surface Disease - Histatins may be used for corneal wound healing and as a treatment for ocular surface disease in humans and other animals. For example, histatins could be included in eye drops, eye gels, ointment, glue, or embedded in (polymer) contact lenses. | 11-21-2013 |
| 20130310327 | Histatin for Corneal Wound Healing and Ocular Surface Disease - Histatins may be used for corneal wound healing and as a treatment for ocular surface disease in humans and other animals. For example, histatins could be included in eye drops, eye gels, ointment, glue, or embedded in (polymer) contact lenses. | 11-21-2013 |
| 20140005125 | DESIGNED ANKYRIN REPEAT PROTEINS BINDING TO PLATELET-DERIVED GROWTH FACTOR | 01-02-2014 |
| 20140018305 | ALPHA CONNEXIN C-TERMINAL (ACT) PEPTIDES FOR TREATING AGE-RELATED MACULAR DEGENERATION - Provided herein are compositions and methods for use in treating or preventing macular degeneration in a subject. | 01-16-2014 |
| 20140018306 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS - The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. | 01-16-2014 |
| 20140045773 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES - Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery. | 02-13-2014 |
| 20140080765 | NOVEL METALLOPROTEIN AND PROCESS FOR PRODUCING SAME, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR CORNEAL AND CONJUNCTIVAL DISEASES COMPRISING SAID METALLOPROTEIN - The present invention provides: a novel metalloprotein, i.e., selenium-lactoferrin; and a process for producing the metalloprotein. Selenium-lactoferrin according to the present invention can be produced suitably by adding a selenium salt to a solution containing lactoferrin and/or apolactoferrin and then subjecting the resultant mixed solution to dialysis or ultrafiltration. | 03-20-2014 |
| 20140094419 | INJECTABLE AQUEOUS OPHTHALMIC COMPOSITION AND METHOD OF USE THEREFOR - The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in creating a desirable release profile of therapeutic agent. | 04-03-2014 |
| 20140107041 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY - The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K | 04-17-2014 |
| 20140171376 | Light-Sensitive Chimeric GPCR Protein - A light-sensitive chimeric protein comprising domains from at least two members of the G-protein-coupled-receptor (GPCR) protein super family, which are fused to yield a light-sensitive GPCR chimera capable of coupling a light signal to the signaling cascade of the metabotropic glutamate receptor 6 (mGluR6) is provided for medical therapy and for the manufacture of medicaments for improving vision, in particular for treating loss of vision resulting from retinal photoreceptor degeneration. A first of the at least two GPCR family members contributes domains which mediate the light-sensitivity to the chimeric light-sensitive GPCR protein. This first member belongs to the family of light-sensitive GPCR proteins also called photopigments, and in some embodiments this light-sensitive GPCR protein is melanopsin, in particular human melanopsin. A second of the at least two GPCR family members is mGluR6, which contributes domains for coupling the light signal to the intracellular signalling cascade of mGluR6, which is a native component of the cell membrane of ON-bipolar cells in the inner retina. | 06-19-2014 |
| 20140179621 | Methods for Treating or Preventing Ophthalmological Diseases - This invention relates to methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising administration of an effective amount of a PDGF antagonist and a VEGF antagonist to a mammal in need thereof. | 06-26-2014 |
| 20140187498 | PREDICTING AND TREATING DIABETIC COMPLICATIONS - Compositions and methods for diagnosing, predicting risk of, and/or treating diabetic retinopathy and/or diabetic nephropathy. | 07-03-2014 |
| 20140221295 | MODIFIED BINDING PROTEINS INHIBITING THE VEGF-A RECEPTOR INTERACTION - The present invention relates to binding proteins specific for Vascular Endothelial Growth Factor A (VEGF-A), in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx (wherein xxx denotes the amino acid length of the VEGF-A mature protein) binding to Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2). Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration. | 08-07-2014 |
| 20140235553 | COMPOSITIONS AND METHODS FOR INTRODUCTION OF MACROMOLECULES INTO CELLS - Disclosed are novel compositions and methods for introduction of macromolecules and nanoparticles into living cells. The invention includes a polypeptide sequence which when fused to a macromolecule or nanoparticle enhances its introduction into the cell. | 08-21-2014 |
| 20140235554 | OPHTHALMIC FORMULATION DERIVED FROM SILK PROTEIN - An ophthalmic composition is described for the treatment of dry eye syndrome in a human or mammal. The composition comprises an aqueous solution including an effective amount of silk protein. The aqueous solution comprises from about 0.01% by weight to about 30% by weight of the silk protein. In one embodiment, the silk protein may be fibroin. A method of treating an eye having an ocular surface is also described. The method comprises providing an ophthalmic composition comprising an aqueous solution including an effective amount of silk protein, and administering the ophthalmic composition topically to the ocular surface. | 08-21-2014 |
| 20140274910 | BETA-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS FOR TREATING DRY EYE - The present invention relates to methods of treating dry eye using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye. | 09-18-2014 |
| 20140296159 | Method for Therapeutic Replenishment and Enrichment of Ocular Surface Lubrication - The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration. | 10-02-2014 |
| 20140364379 | TWO PART FORMULATION SYSTEM FOR OPHTHALMIC DELIVERY - Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent. | 12-11-2014 |
| 20140371161 | NOVEL PEPTIDES AND METHODS AND USES THEREOF FOR PREVENTING RETINAL DISORDERS - The present disclosure relates to methods and uses of C-terminal peptides for inhibiting neuronal cell death or dysfunction, such as retinal ganglion cell death or dysfunction, treating retinal degenerative disorders, stroke, CNS and PNS insults. The disclosure also relates to the C-terminal peptides, fusion proteins and compositions thereof. | 12-18-2014 |
| 20150018287 | EYE DROPS - An eye drop containing (i) a peptide having an amino acid sequence which is represented by Ser-Ser-Ser-Arg (“SSSR”), or a pharmaceutically acceptable salt thereof and (ii) a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH | 01-15-2015 |
| 20150018288 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS - The disclosure provides methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. More specifically, the disclosure provides a composition for preventing, treating, or ameliorating the symptoms of diabetic macular edema in a mammalian subject in need thereof, comprising: a therapeutically effective amount of a peptide D-Arg-2′6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof. | 01-15-2015 |
| 20150031629 | OPHTHALMIC FORMULATION DERIVED FROM SILK PROTEIN - An ophthalmic composition is described for the treatment of dry eye syndrome in a human or mammal. The composition comprises an aqueous solution including an effective amount of silk protein. The aqueous solution comprises from about 0.01% by weight to about 30% by weight of the silk protein. In one embodiment, the silk protein may be fibroin. A method of treating an eye having an ocular surface is also described. The method comprises providing an ophthalmic composition comprising an aqueous solution including an effective amount of silk protein, and administering the ophthalmic composition topically to the ocular surface. | 01-29-2015 |
| 20150038432 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DEGENERATION - The present invention relates to a pharmaceutical composition comprising an inhibitor of eIF2α, a compound increasing the expression and/or activity of protein BiP and/or an inhibitor of Caspase-12, preferably an inhibitor of eIF2α and a compound increasing the expression and/or activity of protein BiP. The present invention also relates to pharmaceutical compositions and methods for treating retinal degeneration related to ciliary dysfunction. | 02-05-2015 |
| 20150038433 | Clusterin Pharmaceuticals and Treatment Methods Using the Same - Disclosed are pharmaceutical compositions comprising clusterin and polypeptides substantially the same as clusterin and treatment methods for inflammatory diseases and dry eye disease. The pharmaceutical compositions include an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The clusterin is preferably secreted clusterin. The method of treating dry eye disease includes administering to a patient in need an effective amount of a pharmaceutical composition comprising an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The method of treating a disease state characterized by inflammation includes administering to a patient having the disease state an amount of isolated clusterin or a protein substantially the same as clusterin effective to decrease the activity of a matrix metallproteinase selected from the group consisting of MMP-9, MMP-2 and MMP-7. | 02-05-2015 |
| 20150119338 | USES OF MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE - The present invention relates to new uses of modified human tumor necrosis factor receptor-1 (TNFRI) polypeptide, and more particularly, to uses thereof for prevention and treatment of dry eye syndrome. The modified TNFRI or modified TNFRI fragment of the present invention has excellent TNFα neutralizing activity, and inhibits TNFα activity on the ocular surface of the patient to suppress inflammation induction effects related to dry eye. Therefore, the modified TNFRI or modified TNFRI fragment of the present invention exhibits remarkable effects in the prevention and treatment of dry eye syndrome, and thus can be very useful in the prevention and treatment of dry eye syndrome. | 04-30-2015 |
| 20150126457 | NEUROPROTECTIVE COMPOSITION AND METHOD OF USE - A therapeutic composition for treating brain injury comprising a polyarginine peptide of from 5 to 9 arginines, and further comprising 1 or more terminal cysteines. The composition is administered in therapeutically effective dosages prophylactic ally as soon as possible post-injury in treating neuronal injury. | 05-07-2015 |
| 20150126458 | METHOD OF TREATING CONDITIONS OF THE EYE WITH AN ANTI-VEGF DARPIN - Disclosed herein are methods for the treatment of a patient having an exudative age-related macular degeneration and other conditions of the retina by administering a binding protein comprising an ankyrin repeat domain, wherein the binding protein is first administered in 2 to 5 doses, with an interval of 25 to 35 days between each dose, and then is administered in additional doses with a longer interval between doses. | 05-07-2015 |
| 20150141348 | SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY - The present invention provides an ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein said complex is associated with a biocompatible polymer. Said biocompatible polymer comprises a polymeric matrix configured to release said complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease. | 05-21-2015 |
| 20150291672 | Contact Lens Surface Modification with Hyaluronic Acid (HA) Binding Peptide for HA Accumulation and Retention - An embodiment in accordance with the present invention provides a device and method for providing HA to the ocular environment. A contact lens according to the present invention is treated at its surface with a HA binding peptide. The HA binding peptide can be covalently bonded to a functional group on the surface of the contact lens, such as OH, COOH, or NH2. The lens can then be pretreated with HA for immediate increased wearer comfort upon insertion of the lens. As HA is washed away or degraded from the surface of the lens, the HA binding peptide remains and therefore HA can be replenished from endogenous or exogenous sources. | 10-15-2015 |
| 20150306084 | ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION - The present invention relates to the use of selective adenosine A1 agonists, in particular the dicyanopyridines of formula (I), for the treatment and/or prophylaxis of glaucoma and ocular hypertension as well as the their use for the production of a medicament for the treatment and/or prophylaxis of glaucoma and ocular hypertension. | 10-29-2015 |
| 20150320831 | PROTEIN SLURP-1 FOR USE IN THE TREATMENT OF OCULAR DISEASES - The present invention relates to a protein comprising SEQ ID NO:1 (mature form of SLURP-1) and to a composition comprising the same for use in inducing or accelerating cicatrisation, and/or in preventing infection in the eye of a subject. | 11-12-2015 |
| 20150335707 | USE OF SLURP1 AS AN IMUNOMODULATORY MOLECULE IN THE OCULAR SURFACE - Methods for treating inflammation are disclosed, such as for treating ocular inflammation. In some embodiments, the ocular inflammation is inflammation of an ocular surface, such as keratitis. The methods include administering to a subject with inflammation a therapeutically effective amount of SLURP1, or a nucleic acid encoding SLURP1, thereby treating the inflammation. | 11-26-2015 |
| 20160000809 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF EYE PAIN, CONTAINING PGE2 SYNTHESIS INHIBITOR - The present invention relates to a pharmaceutical composition for the treatment of eye pain, containing a PGE2 synthesis inhibitor. The use of the pharmaceutical composition for the prevention or treatment of eye pain according to the present invention, which contains the PGE2 synthesis inhibitor as an active ingredient, makes it possible to alleviate the symptoms of eye pain by selectively inhibiting the PGE2 expression level, and also has the advantages of treating and preventing xerophthalmia and of overcoming and preventing eye discomfort caused by various inflammation-inducing circumstances including following surgery. Also, by using a kit for detecting the amount of PGE2, PGD2 and COX2, the present invention makes it possible to easily diagnose eye-pain symptoms in clinical practice, and can be widely used in checking the state not only of patients having xerophthalmia but also patients following eye surgery. | 01-07-2016 |
| 20160000885 | Methods for Stabilizing Corneal Tissue - Methods of stabilizing collagen fibrils in a cornea are disclosed. The stabilization may be effected by treating the cornea with a protein that crosslinks collagen fibrils, such as decorin. The stablization methods include treatment of corneas before, during, or after a surgical procedure, treatment of keratectasia, and treatment of keratoconus. | 01-07-2016 |
| 20160002641 | INHIBITION OF SEMA3A IN THE PREVENTION AND TREATMENT OF OCULAR HYPERPERMEABILITY - Described herein is a method of preventing or treating ocular vascular hyperpermeability including macular edema, in a subject comprising inhibiting Sema3A activity. Also disclosed are compositions and their use for preventing or treating Sema3A-dependent ocular vascular hyperpermeability. | 01-07-2016 |
| 20160017004 | METHODS AND THERAPEUTICS COMPRISING LIGAND-TARGETED ELPs - Disclosed herein are novel methods and compositions for targeting drug delivery systems to specific cells. One aspect relates to a drug delivery system comprising an elastin-like peptide (ELP) component and a ligand selected from the group consisting of mIgA and knob capable of either drug encapsulation or drug attachment. Further aspects relate to drug delivery systems comprising an elastin-like peptide (ELP) component and a ligand; wherein the ligand specifically binds to a receptor selected from the group consisting of CAR and pIgR. Further aspects include the novel transcytosing properties of the elastin-like peptide and the ligand, knob. Also provided are methods and pharmaceutical compositions comprising the disclosed therapeutics. | 01-21-2016 |
| 20160022769 | COMPOSTIONS AND METHODS FOR TREATING RETINAL DISEASE - The invention provides methods, compositions, and kits featuring Wnt signaling enhancing compounds for use in preventing or treating retinal disease. | 01-28-2016 |
| 20160024580 | POLYMORPHISM OF THROMBOSPONDIN-1 AS A BIOMARKER FOR SUSCEPTABILTIY TO DRY EYE - Embodiments of the invention relate to single nucleotide polymorphisms (SNPs) in Thrombospondin 1 gene (THB-S1) that are herein linked to an increased risk for dry eye (also known as keratoconjunctivitis). The polymorphisms disclosed herein are directly useful for the diagnosis of an increased risk for dry eye, as well as for the determination of patient treatment pre- and post-surgery (e.g. pre and post refractive eye surgery) or in a patient having a condition associate with dry eye (e.g. diabetes, lupus, scleroderma, Sjogren's syndrome, thyroid disorders, vitamin A deficiency, and rheumatoid arthritis). Computer systems and medium are also enclosed. The SNPs can be present in unique combinations, or as specific haplotypes indicative of dry eye. The SNPs linked to an increased risk for dry eye include rs1478604, rs2228261, and rs2292305. | 01-28-2016 |
| 20160038560 | ANGIOTENSIN PEPTIDES IN TREATING MARFAN SYNDROME AND RELATED DISORDERS - The present invention provides, among other things, methods of treating Marfan Syndrome and/or a Marfan-related disorder including administering to a subject suffering from or susceptible to Marfan Syndrome and/or a Marfan-related disorder an angiotensin (1-7) peptide. In some embodiments, the angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one symptom or feature of Marfan Syndrome and/or a Marfan-related disorder is reduced in intensity, severity, duration, or frequency or has delayed in onset. | 02-11-2016 |
| 20160039890 | INTRAOCULAR ANGIOGENESIS INHIBITOR AND USES THEREOF - Intended is to provide a new therapeutic or prophylactic means for intraocular angiogenesis. Provided is an intraocular angiogenesis inhibitor including a polypeptide which is a variant of diphtheria toxin, and shows activity inhibiting binding between HB-EGF and an EGF receptor. | 02-11-2016 |
| 20160039892 | ARTIFICIAL TRANSCRIPTION FACTORS AND THEIR USE FOR THE TREATMENT OF MALADAPTED WOUND HEALING IN THE EYE - The invention relates to artificial transcription factors comprising polydactyl zinc finger proteins targeting promoters of genes involved in maladapted wound healing in the eye. Such artificial transcription factors are useful for the treatment of fibrocontractive retinal disorders, such asepiretinal gliosis, proliferative vitreoretinopathy, proliferative diabetic retinopathy and epiretinal membrane, and for the treatment of fibroplasia associated with glaucoma surgery. | 02-11-2016 |
| 20160039893 | ARTIFICIAL TRANSCRIPTION FACTORS FOR THE TREATMENT OF DISEASES CAUSED BY OPA1 HAPLOINSUFFICIENCY - The invention relates to an artificial transcription factor comprising a polydactyl zinc finger protein targeting specifically the OPA1 promoter fused to an activatory protein domain, and a nuclear localization sequence. Artificial transcription factors directed against the OPA1 promoter are useful for the treatment of diseases associated with OPA1 haploinsufficiency, such as autosomal dominant optic atrophy, syndromic autosomal dominant optic atrophy plus and normal tension glaucoma. | 02-11-2016 |
| 20160082072 | BETA-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS FOR TREATING DRY EYE - The present invention relates to methods of treating dry eye using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye. | 03-24-2016 |
| 20160089413 | USE OF CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY FOR THE TREATMENT OF CHRONIC OR NON-CHRONIC INFLAMMATORY EYE DISEASES - The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory eye diseases, such as inflammatory diseases of the blephara, conjunctiva, cornea, sclera, the vitreous body, uvea, ciliary body, choroid, orbital bone, lacrimal gland, or iris, in particular wherein the inflammatory disease is selected from hordeolum, chalazion, conjunktivitis, keratitis, scieritis, episcleritis, endophthalmitis, panophtalmitis, irititis, uveitis, cyclitis, chorioiditis, orbital phlegmon, and myositis of the eye muscle etc. | 03-31-2016 |
| 20160095937 | INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF - The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided. | 04-07-2016 |
| 20160096878 | FIBROIN-DERIVED PROTEIN COMPOSITION - The invention provides a protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa. | 04-07-2016 |
| 20160101149 | Method for Therapeutic Replenishment and Enrichment of Ocular Surface Lubrication - The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes discomfort at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, or a lubricating fragment thereof, suspended in an ophthalmically acceptable vehicle. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration. | 04-14-2016 |
| 20160108099 | VECTORS ENCODING ROD-DERIVED CONE VIABILITY FACTOR - The present invention relates to nucleic acids coding for and capable of expressing a rod-derived cone viability factor (RdCVF) and viral vectors containing these nucleic acids. The invention also relates to compositions and pharmaceutical preparations comprising these nucleic acids or vectors, methods of producing or secreting an RdCVF, and methods of treatment. | 04-21-2016 |
| 20160151457 | OPHTHALMIC USES OF TOXIN-BASED THERAPEUTIC PEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | 06-02-2016 |
| 20160185832 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISORDERS RELATED TO CEP290 - Compositions are provided that comprise a recombinant vector carrying a nucleic acid sequence encoding a fragment of CEP290 lacking all or part of its N-terminal and C-terminal inhibitory regions, under the control of regulatory sequences which express the product of said gene in a selected cell of a mammalian subject, and a pharmaceutically acceptable carrier. These and other compositions are disclosed with are useful in methods for treating a mammalian subject having a disease associated with a CEP290 mutation, such as Lebers Congenital Amaurosis. | 06-30-2016 |
| 20190142915 | OCULAR DELIVERY OF CELL PERMEANT THERAPEUTICS FOR THE TREATMENT OF RETINAL EDEMA | 05-16-2019 |
| 20100286030 | NOVEL BACTERIOCIN FROM A NEW STREPTOMYCES SPECIES - Provided is an isolated novel Gram-positive non-motile, non-spore-forming, aerobic bacterium designated | 11-11-2010 |
| 20100292136 | POLYMYXIN DERIVATIVES AND USES THEREOF - The present invention relates to a polymyxin derivative wherein R1, R2 and R3 are optional and R1, R2, R3, R5, R8 and R9 are cationic or neutral amino acid residues selected so that the total number of positive charges at physiological pH is at least two but no more than three; and to a combination product comprising at least two such derivatives. The invention further relates to a method for treating, alleviating or ameliorating an infection in a subject, caused by a Gram-negative bacterium by administering a therapeutically effective amount of a derivative according to the present invention to said subject; to a method for sensitizing Gram-negative bacteria to an antibacterial agent by administering, simultaneously or sequentially in any order a therapeutically effective amount of said antibacterial agent and a derivative according to the present invention to said subject; to methods for developing novel antibiotics; for reducing the nephrotoxicity, for improving the pharmacokinetic properties of natural polymyxins and octapeptins; and for sensitizing clinically important bacteria to a host defense mechanism complement present in serum. Finally, the invention relates to a process for preparing such polymyxin derivatives. | 11-18-2010 |
| 20100305026 | CD44V6 peptides as inhibitors of bacterial infections - The present invention relates to the use of peptide compounds for the prevention and/or treatment of a bacterial infection. | 12-02-2010 |
| 20100305027 | CYCLIC PEPTIDES COMPRISING AT LEAST ONE AZA-B3-AMINOACYL RESIDUE AND THEIR USES - Cyclic peptides having a random alternation of L-α-aminoacyl residues and aza-β | 12-02-2010 |
| 20100331242 | METHOD OF USING LECTINS FOR PREVENTION AND TREATMENT OF ORAL AND ALIMENTARY TRACT DISORDERS - Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with | 12-30-2010 |
| 20110003734 | PROTEINS AND POLYNUCLEOTIDES OF VIBRIO CHOLERAE - Therapeutic, diagnostic and environmental monitoring methods employing proteins encoded by the rbmBCDEF gene cluster and by bap1. | 01-06-2011 |
| 20110015118 | C-Terminal Ifapsoriasin Fragments as Antimicrobial Peptides, the Production Thereof and Use Thereof - The present invention relates to novel C-terminal ifapsoriasin fragments as antimicrobially acting peptides and their production and use as pharmaceuticals. | 01-20-2011 |
| 20110021416 | COMPOSITIONS, METHODS AND USES FOR TREATING BACTERIAL INFECTIONS - A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), | 01-27-2011 |
| 20110082074 | AGENT FOR PREVENTING PERIODONTAL DISEASE - The present invention provides a pharmaceutical agent that is useful for preventing periodontal disease. The pharmaceutical agent contains a compound in which a mucin-type sugar chain-binding lectin is bound to a polypeptide having an integrin recognition sequence. | 04-07-2011 |
| 20110144002 | Use of AMPs for Treatment of UTI/Cystitis - The present invention relates to methods for treating urinary tract infections, such as cystitis, with antimicrobial polypeptides polypeptides. | 06-16-2011 |
| 20110160125 | METHOD AND CULTURE MEDIUM FOR ENHANCED DETECTION OF MYCOBACTERIUM - The present invention relates to an improved culture medium and method for the enhanced growth and detection of | 06-30-2011 |
| 20110166060 | TYMPANIC MEMBRANE PERMEATING EAR DROPS AND USES THEREOF - The present invention provides compositions and methods for noninvasive delivery of therapeutic agents across an intact tympanic membrane. For example, the compositions include a penetration enhancer which increases the flux of a therapeutic agent (e.g., antibiotic) across the tympanic membrane. Such compositions are particularly useful in the treatment of otitis media. Additionally, the composition may include a sustained release agents that, in some embodiments form sustained release reservoirs, in situ, once administered to a patient. | 07-07-2011 |
| 20110218139 | COMBINATION THERAPY AND METHODS FOR TREATING BACTERIAL BIOFILMS - A combination therapy for treating a bacterial biofilm comprises a therapeutically effective amount of an antibiotic comprising an aminoglyco side or tetracycline, or a combination of two or more thereof, and a cationic porphyrin in an amount effective for enhancing the effectiveness of the antibiotic in treating the bacterial biofilm. A method of treating a bacterial biofilm comprising | 09-08-2011 |
| 20110230395 | Antibacterial agent based on fatty acid esters of hydroxy carboxylic acids - An antibacterial composition includes a combination of fatty acid ester of fatty acid and hydroxy carboxylic acid with an antibacterial agent selected from polylysine, chitosan, protamine, their salts and mixtures hereof. The hydroxy carboxylic acid may be present as acid in its free form, in its salt form and/or in its ester form. The composition may be used as an antibacterial agent against gram-negative bacteria in various products, applications and methods. | 09-22-2011 |
| 20110269671 | NISIN DERIVATIVES AND THE USE THEREOF - The present invention relates to a nisin derivative comprising amino acid substitutions in the peptide sequence encoding the hinge region of the protein, wherein the derivative exhibits an increased anti-microbial activity. | 11-03-2011 |
| 20110288008 | ANTIBACTERIAL AND PLASMID ELIMINATION AGENTS - Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, including | 11-24-2011 |
| 20110294724 | LOW HEMOLYTIC ANTIMICROBIAL PEPTIDE, PHARMACEUTICAL COMPOSITION AND USE THEREOF - Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P | 12-01-2011 |
| 20120058936 | COMPOSITIONS AND METHODS FOR ELIMINATION OF GRAM NEGATIVE BACTERIA - Oral drug delivery formulations which specifically administer antibacterial agents to the ileum, caecum, and/or the colon, without significant administration elsewhere in the gastrointestinal tract, are disclosed. The formulations include, as actives, a combination of a macrolide or aminoglysoside, or quinolone antibacterial and an anti-Gram-negative lipopeptide (polymyxin) antibacterial agent or other peptide antibacterials effective against Gram-negative bacteria. The formulations can be used to treat infections or unwanted colonization in the colon, and to provide effective decontamination of the colonic flora from unwanted or potentially pathogenic bacteria. | 03-08-2012 |
| 20120122768 | ALGINATE OLIGOMERS FOR USE IN OVERCOMING MULTIDRUG RESISTANCE IN BACTERIA - The invention provides a method of overcoming resistance to at least one antibiotic in a multidrug resistant bacterium, said method comprising contacting said bacterium with an alginate oligomer together with the antibiotic. The multidrug resistant bacterium may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium to overcome resistance to the antibiotic in said multidrug resistant bacterium. In another aspect the method can be used to combat contamination of a site with multidrug resistant bacteria, e.g. for disinfection and cleaning purposes. | 05-17-2012 |
| 20120135917 | Anti-Gram Negative Bacteria Agent - Provided are: a method for blocking the biosynthesis of an outer membrane protein (OMP) necessary for the survival of Gram-negative bacteria by inhibiting the formation of a YaeT complex in the outer membrane of the bacteria and an agent therefor for the purpose of basically solving a problem of the development of multidrug resistance in Gram-negative bacteria. Specifically disclosed is an anti-Gram-negative bacteria agent, wherein the agent exerts a bactericidal action, a growth-inhibiting action, and/or a drug efflux-inhibiting action on Gram-negative bacteria by inhibiting the formation of a YaeT complex. The agent is preferably a peptide molecule comprising an amino acid sequence consisting of at least LTLR or a peptide molecule comprising an amino acid sequence consisting of at least FIRL. | 05-31-2012 |
| 20120149631 | ANTIMICROBIAL AND ANTIBIOFILM ACTIVITY OF CATHELICIDINS - The present disclosure relates to peptides, and fragments thereof, conferring antimicrobial and/or antibiofilm growth, as well as products and methodology for using same. | 06-14-2012 |
| 20120157374 | NODULE SPECIFIC MEDICAGO PEPTIDES HAVING ANTIMICROBIAL ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINGING THE SAME - The present invention relates to the use of at least one peptide originated from | 06-21-2012 |
| 20120208744 | ANTI-MICROBIAL AGENTS AND COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF - Anti-microbial compositions for inhibiting gram-negative bacterial growth include inhibitors of one or more interactions between the bacterial proteins TonB and ExbD and/or between the bacterial proteins TolR and TolA. Methods of producing and using the anti-microbial compositions (e.g., treating gram-negative bacterial infections in a mammalian subject) are described. Novel antibiotics that target the TonB system and prevent bacterial growth are described herein. | 08-16-2012 |
| 20120283175 | ANTIBACTERIAL COMPOSITIONS - The present invention provides a methods and pharmaceutical compositions useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, a synergistic combination of an inhibitor of LpxC and second antibacterial agent. | 11-08-2012 |
| 20120283176 | SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF - The present invention relates to a polymyxin derivative wherein the derivative has a total of three positive charges at physiological pH and wherein the terminal moiety (D) of the derivative comprises a total of 1 to 5 carbon atoms The invention also relates to a method of treating a subject for a gram-negative bacterial infection by administering a polymyxin derivative of the invention in combination with a second antibacterial agent. Finally, the invention relates to a process for preparing such polymyxin derivatives. | 11-08-2012 |
| 20120316104 | USE OF BACTERIOPHAGE OUTER MEMBRANE BREACHING PROTEINS EXPRESSED IN PLANTS FOR THE CONTROL OF GRAM-NEGATIVE BACTERIA - The present invention provides compositions and methods for killing or suppressing growth of Gram-negative bacteria that infect, infest or cause disease in plants, including pathogenic, saprophytic and opportunistic microbes that cause disease in plants and food borne illness in people or in animal feed. | 12-13-2012 |
| 20120316105 | Polymyxin Derivates Useful As Antibacterial Agents - The present invention provides a new class of polymyxin derivates useful for treating bacterial infections, especially Gram-negative infections, that have reduced renal cytotoxicity. | 12-13-2012 |
| 20130072423 | CD44V6 PEPTIDES AS INHIBITORS OF BACTERIAL INFECTIONS - The present invention relates to the use of peptide compounds for the prevention and/or treatment of a bacterial infection. | 03-21-2013 |
| 20130109616 | ANTIMICROBIAL PEPTIDES | 05-02-2013 |
| 20130116168 | PEA PROTEIN PEPTIDES WITH ANTI HELICOBACTER PYLORI ACTIVITY - The invention relates to a composition comprising pea protein hydrolysate for the treatment and/or prevention of infection by gastrointestinal pathogens, in particular | 05-09-2013 |
| 20130196900 | ENHANCEMENT OF INNATE RESISTANCE TO INFECTION - The present invention provides compounds and compositions that enhance the innate immune system. The present invention comprises methods of preventing, treating or ameliorating an infectious disease comprising administering said compounds to a subject. The invention also comprises methods of formulation and administration of said compounds. | 08-01-2013 |
| 20130196901 | Neisseria Porin Protiens - PorA constructs are provided which have one or more disrupted variable regions created by insertion of entire conserved regions or conserved region amino acids. The highly immunogenic variable regions of PorA are responsible for eliciting strain-specific immune responses that are not broadly protective, so disruption of the variable regions directs the immune response against conserved region epitopes to effectively immunize against a broader spectrum of | 08-01-2013 |
| 20130252881 | Transcription Factor Decoys - Decoy nucleic acid sequences comprising a sequence encoding all or part of a binding site for bacterial sigN alternative sigma54 factor are described. Uses of the decoys in antibacterial complexes and for the treatment of bacterial infections are also described. | 09-26-2013 |
| 20130252882 | ANTIMICROBIAL 4-OXOQUINOLIZINES - This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents. | 09-26-2013 |
| 20130288953 | USE OF A COMPOSITION COMPRISING AN ANTIMICROBIAL PEPTIDE AS A FOOD PRESERVATIVEUSE OF A COMPOSITION COMPRISING AN ANTIMICROBIAL PEPTIDE AS A FOOD PRESERVATIVE - The inventors provide the use of a composition comprising an antimicrobial polypeptide comprising Blad or an active variant thereof to prevent or inhibit spoilage of a foodstuff by a microorganism. Also provided is a method of preventing or inhibiting spoilage of a foodstuff by a microorganism comprising administering to a foodstuff in need thereof an effective amount of a composition comprising an antimicrobial polypeptide comprising Blad or an active variant thereof. | 10-31-2013 |
| 20130288954 | USE OF CHELATING AGENT AND PEPTIDE ANTIMICROBIAL COMPOUNDS - The inventors provide the use of a chelating agent and an antimicrobial agent that is effective against a plant pathogenic microorganism to inhibit the growth of and/or kill a plant pathogenic microorganism on a plant; the use of a chelating agent to increase the activity of an antimicrobial that is effective against a plant pathogenic microorganism; a method of inhibiting the growth of and/or killing a plant pathogenic microorganism comprising administering to a plant in need thereof a chelating agent and an antimicrobial agent that is effective against a plant pathogenic microorganism; and a method of increasing the activity of an antimicrobial that is effective against a plant pathogenic microorganism comprising using said antimicrobial with a chelating agent. Also provided is a composition comprising a chelating agent and an antimicrobial agent that is effective against a plant pathogenic microorganism, use of said composition to inhibit the a growth of and/or kill a plant pathogenic microorganism on a plant, and a method of inhibiting the growth of and/or killing a plant pathogenic microorganism comprising administering to a plant in need thereof said composition. Further provided is the use of a composition comprising an antimicrobial polypeptide comprising Blad or an active variant thereof to kill, or inhibit the growth of a plant pathogenic bacterium on a plant, and a method of killing, or inhibiting the growth of a plant pathogenic bacterium on a plant, said method comprising administering to said plant a composition comprising an effective amount of an antimicrobial polypeptide comprising Blad or an active variant thereof. | 10-31-2013 |
| 20130345121 | Antibiotic Compositions For The Treatment of Gram Negative Infections - Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin B | 12-26-2013 |
| 20140031275 | METHODS OF ERADICATING BACTERIAL CELL POPULATIONS - Disclosed herein are methods and compositions for the eradication of bacterial infections. In particular, methods and compositions are disclosed for the eradication of persister and slow growing bacterial cell populations. In particular embodiments, the methods and compositions disclosed herein are useful for eradication of biofilms. | 01-30-2014 |
| 20140073559 | Antibiotic Compositions for the Treatment of Gram Negative Infections - Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds. | 03-13-2014 |
| 20140073560 | CITROBACTER FREUNDII ANTIBACTERIAL AGENTS AND THEIR USE - Provided herein are methods for treating planktonic bacteria or a biofilm. The methods include contacting the planktonic bacteria or biofilm with an effective amount of an isolated | 03-13-2014 |
| 20140142030 | SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF - The present invention relates to a polymyxin derivative wherein the derivative has a total of three positive charges at physiological pH and wherein the terminal moiety (D) of the derivative comprises a total of 1 to 5 carbon atoms. The invention also relates to a method of treating a subject for a gram-negative bacterial infection by administering a polymyxin derivative of the invention in combination with a second antibacterial agent. Finally, the invention relates to a process for preparing such polymyxin derivatives. | 05-22-2014 |
| 20140162937 | POLYMYXIN DERIVATIVES AND USES THEREOF - The present invention relates to a polymyxin derivative and to a combination product comprising at least two such derivatives. The invention further relates to a method for treating, alleviating or ameliorating an infection in a subject caused by a Gram-negative bacterium, by administering a therapeutically effective amount of a derivative according to the present invention to said subject; to a method for sensitizing Gram-negative bacteria to an antibacterial agent by administering, simultaneously or sequentially in any order a therapeutically effective amount of said antibacterial agent and a derivative according to the present invention to said subject; to methods for developing novel antibiotics; for reducing the nephrotoxicity, for improving the pharmacokinetic properties of natural polymyxins and octapeptins; and for sensitizing clinically important bacteria to a host defense mechanism complement present in serum. Finally, the invention relates to a process for preparing such polymyxin derivatives. | 06-12-2014 |
| 20140162938 | PEPTIDE COMPOUNDS AND METHODS OF PRODUCTION AND USE THEREOF - Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptides. | 06-12-2014 |
| 20140171358 | ANTIMICROBIAL COMPOSITIONS COMPRISING DGLA AND NEOMYCIN SULFATE AND METHODS OF USE THEREOF - The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used alone or in combination with one or more antibiotic agents for the treatment of disease and/or disorders such as a skin infection or wound healing. | 06-19-2014 |
| 20140187474 | THERAPEUTIC USE OF MUCIN GLYCANS - A therapeutic formulation containing mucin glycans derived from one or a number of nutritionally appropriate sources is described. | 07-03-2014 |
| 20140194346 | PASTEURELLACEAE VACCINES - The present invention relates to an N-glycosylated protein for treating and/or preventing bacterial Pasteurellaceae infection in a mammal or bird, wherein the protein is a Pasteurellaceae protein, a functional fragment or derivative thereof having at least one glycosylated N-X-S/T consensus sequence. In addition, the present invention is directed to corresponding pharmaceutical compositions for treating and/or protecting mammals or birds having or being prone to develop a bacterial Pasteurellaceae infection. Furthermore, the invention describes methods for producing said N-glycosylated proteins. | 07-10-2014 |
| 20140235532 | IMMUNOGENIC ESCHERICHIA COLI HEAT STABLE ENTEROTOXIN - The present invention relates to methods and compositions for the treatment and prevention of diarrhea and diarrheal related diseases and disorders in both animals and humans. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders with a vaccine. In still further embodiments, the invention relates to the treatment of constipation using the disclosed methods and compositions. | 08-21-2014 |
| 20140274880 | MOSQUITOCIDAL XENORHABDUS, LIPOPEPTIDE AND METHODS - Provided is a bacterial strain which produces a family of mosquitocidal toxins, | 09-18-2014 |
| 20140371134 | Dry Pharmaceutical Compositions for Topical Delivery of Oral Medications, Nasal Delivery and to Treat Ear - In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent. | 12-18-2014 |
| 20150031602 | Compounds - Provided are compounds, the use of the said compounds in treatment, for example treatment of microbial infections, particularly by Gram negative bacteria. The compounds are polymyxin-based and are represented by the formula (I): | 01-29-2015 |
| 20150045287 | ANTIMICROBIAL COMPOSITION FOR INHIBITING MICROBIAL ORGANISMS AND THE METHOD THEREOF - The invention relates to a method of controlling or combating microbial organism by applying an antimicrobial peptide to the microbial organisms, wherein said antimicrobial peptide derived from | 02-12-2015 |
| 20150045288 | COMPOSITION - The present invention relates to anti-contaminant composition comprising a cell-free fermentation product of one or more | 02-12-2015 |
| 20150065416 | NOVEL DRUG COMBINATION - There is provided inter alia a method of treating microbial infection comprising administering to a subject in need thereof a therapeutically effective amount of:
| 03-05-2015 |
| 20150126435 | PRIMERS, ASSAYS AND METHODS FOR DETECTING AN E. COLI SUBTYPE - Disclosed are primers, probes, and single nucleotide polymorphisms (SNP) specific to a distinct subclones of the | 05-07-2015 |
| 20150141324 | STABLE PEPTIDE-BASED FURIN INHIBITORS - It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutically effective amount of the furin inhibitors or the composition disclosed, thereby preventing or treating pathogen infection, in the subject. | 05-21-2015 |
| 20150290278 | CATIONIC ANTIMICROBIAL PEPTIDES - A method for treating an infection comprises administering a peptide in synergistic combination with an antibiotic, wherein the peptide comprises an amino acid sequence with a formula selected from the group consisting of: | 10-15-2015 |
| 20150306238 | BACTERIA TARGETING NANOPARTICLES AND RELATED METHODS OF USE - The present invention relates to bacteria-targeting nanoparticles and related methods of use. In particular, the present invention relates to dendrimer nanoparticles conjugated with Vancomycin and/or Polymixin (e.g., Polymixin B, Polymixin E). In certain embodiments, such dendrimer nanoparticles are used to sequester and/or identify bacteria (e.g., Gram-positive bacteria and/or Gram-negative bacteria), screen liquid samples (e.g., water samples, food samples, pharmaceutical samples, blood samples, blood platelet samples, etc.) for the presence of bacteria (e.g., Gram-positive bacteria and/or Gram-negative bacteria), treat disorders associated with bacteria (e.g., Gram-positive bacteria and/or Gram-negative bacteria), and/or identify, sequester, and remove bacteria (e.g., Gram-positive bacteria and/or Gram-negative bacteria) from a liquid sample (e.g., water sample, food sample, pharmaceutical sample, blood sample, blood platelet sample, etc.). In certain embodiments, iron oxide nanoparticles are coated with dendrimer nano-particles conjugated with Vancomycin and/or Polymixin. | 10-29-2015 |
| 20150374785 | Peptide Compounds and Methods of Production and Use Thereof - Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptides. | 12-31-2015 |
| 20160002296 | POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE - Disclosed herein is a composition comprising at least one polymyxin or a salt thereof represented by formula (I) wherein R | 01-07-2016 |
| 20160002300 | ANTIMICROBIAL PEPTIDES DERIVED FROM HEPATITIS B VIRUS CORE PROTEIN ARGININE-RICH DOMAIN - A pharmaceutical composition for use in killing and/or inhibiting the growth and/or proliferation of a microorganism in a subject in need thereof, or for treating a subject afflicted with a microbial infection is disclosed. The composition comprises: (a) an effective amount of an isolated peptide, wherein the peptide comprises the arginine-rich carboxy-terminal region of hepatitis B virus core protein (HBc) and exhibits an antimicrobial activity; and (b) a pharmaceutically acceptable carrier. The peptide exhibits an activity against Gram-negative bacteria, Gram-positive bacteria, and/or fungi. | 01-07-2016 |
| 20160025725 | METHOD FOR IDENTIFYING A BACTERIAL INFECTION - Method for identifying a bacterial infection The present application concerns a method for identifying the nature of a bacterial infection from a peritoneal sample, in particular, whether it is a Gram-negative or Gram-positive infection, based upon the determination of one or more cellular and/or humoral markers in a sample. | 01-28-2016 |
| 20160052971 | BETA-HAIRPIN PEPTIDOMIMETICS - Beta-hairpin peptidomimetics of the general formula (I), cyclo[P | 02-25-2016 |
| 20160060315 | PEPTIDE COMPOUNDS AND METHODS OF PRODUCTION AND USE THEREOF - Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptide compounds. | 03-03-2016 |
| 20160122389 | PEPTIDES WITH ANTAGONISTIC ACTIVITIES AGAINST NATURAL CXCR4 - A peptide effective in blocking the CXC-chemokine receptor 4 (CXCR4) mediated HIV-1 NL4-3 (X4-tropic) infection with an IC | 05-05-2016 |
| 20160157497 | DISPERSION AND DETACHMENT OF CELL AGGREGATES - Compositions comprising a protein or isolated peptide, and methods using the same for preventing, dispersing or detaching a biofilm, are disclosed. | 06-09-2016 |
| 20160158317 | Antimicrobial Peptide Variants and Polynucleotides Encoding Same - The present invention relates to variants of a parent antimicrobial peptide. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 06-09-2016 |
| 20160166548 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | 06-16-2016 |
| 20160175394 | Compositions and Uses of Lectins | 06-23-2016 |
| 20160184396 | HUMAN-ORIGINATED EGF DOMAIN PROTEINS AND USE OF THE SAME - In the invention, the minimum inhibitory concentrations of human-originated EGF domain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity. It has been shown that the human-originated EGF domain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by silver staining that the human-originated EGF domain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia. The amino acid sequences of the human-originated EGF domain proteins are the one described in SEQ ID NO: 1 in the sequence listing, or those having homology of over 50% to the amino acid sequence described in SEQ ID NO: 1. | 06-30-2016 |
| 20160185823 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS - The present invention provides antimicrobial polymyxin compounds of the following formula I: | 06-30-2016 |
| 20170233437 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | 08-17-2017 |
